TYDOCK PHARMA is a biotechnology SME based in Modena, Emilia-Romagna, Italy, with a primary focus on the discovery and early development of chemotherapeutic drugs for parasitic diseases, with particular emphasis on tuberculosis, malaria, and protozoarian infections. The company was established in 2006 and has since become a leading player in the drug discovery field, with over 20 years of experience in integrated drug discovery know-how.
Innovation at its core
TYDOCK PHARMA has a strong foundation in innovation and has received recognition for its contributions to the biotechnology industry. In 2009, the company was awarded for being one of the most promising and innovative biotechnology companies in Italy by The Italian Institute for Foreign Trade (I.C.E.). The company’s research and technology transfer centre has received research grants from the European Commission (FP7) for its innovative projects.
Collaborations for success
TYDOCK PHARMA has seen many successful collaborations with universities and other biotechnology companies. These collaborations have been essential to the development of TYDOCK PHARMA’s integrated drug discovery know-how and have led to the discovery of promising chemotherapeutic drugs for parasitic diseases. The company’s collaborations have also helped to bring innovative technologies from basic research to industrial application.
Drug discovery products for parasitic diseases
TYDOCK PHARMA’s primary business area is the discovery and early development of chemotherapeutic drugs for parasitic diseases, including tuberculosis, malaria, and protozoarian infections. The company’s drug discovery products focus on identifying and developing new drugs that are effective against these parasitic diseases. With the help of its integrated drug discovery know-how, TYDOCK PHARMA has identified promising drug candidates for these diseases and is working to bring them to market.
Innovation project development
TYDOCK PHARMA is also involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application. The company’s innovation project development aims to bring new and innovative technologies to the biotechnology industry, with a focus on improving drug discovery and development processes. These projects have the potential to revolutionize the industry and bring new drugs to market faster and more efficiently.
Conclusion
TYDOCK PHARMA is an innovative biotechnology company with a focus on discovering and developing chemotherapeutic drugs for parasitic diseases. With over 20 years of experience in integrated drug discovery know-how and successful collaborations with universities and other biotechnology companies, TYDOCK PHARMA is a leading player in the drug discovery field. The company’s commitment to innovation and its focus on bringing new technologies to the industry has the potential to revolutionize drug discovery and development processes.
Website: http://www.tydockpharma.com/
Twitter: https://twitter.com/TydockPharma
Facebook: https://www.facebook.com/TydockPharma/
LinkedIn: https://www.linkedin.com/company/tydock-pharma-srl/
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
